新型雌激素受体GPR30激活HER2-ERK1/2促进乳腺癌MCF-7细胞迁移和侵袭

摘要

Objective To study the molecular mechanism and biological significance of GPR30 activating HER2 in MCF-7 breast cancer cells with low expresses HER2.Methods Western blot was adopted to examine the phosphorylation of HER2 and the downstream signaling molecular ERK1/2 after 17-β-estradiol(E2),4-OHT(the active metabolite of tamoxifen) or G-1 (the GPR30 agonist) treatment in MCF-7 cells.After different inhibitors such as G-15 (the GPR30 antagonist),AG1478(EGFR tyrosine inhibitor),AG825 (HER2 tyrosine inhibitor),PP2 (Src family kinase inhibitor)or GM6001 (MMP inhibitor) pretreated for 2 h,the phosphorylation of HER2 and ERK1/2 were further analyzed.Finally,the altered migration and invasive capability of MCF-7 cells were detected by Transwell method.Results HER2 and ERK1/2 were activated in MCF-7 cells after E2,4-OHT or G-1 treatment and these changes could be inhibited by G-15,AG1478,AG825,PP2 or GM6001 pretreatment.The enhancement of G-1-induced migration and invasion ability in MCF-7 cells could also be inhibited by those inhibitors too.Conclusion GPR30 promotes the migration and invasion of MCF-7 cells through activating HER2-ERK1/2 signal transduction pathway.%目的 探讨G蛋白耦联受体30 (GPR30)受体在低表达表皮生长因子受体2(HER2)的乳腺癌MCF-7细胞中激活HER2的分子机制和生物学意义.方法 用Western blot的方法检测17-p-雌二醇(E2)、三苯氧胺(TAM)的活性代谢产物(4-OHT)或GPR30激动剂(G-1)作用于乳腺癌MCF-7细胞后HER2和下游信号分子ERK1/2磷酸化水平的变化.在MCF-7细胞被不同的抑制剂GPR30拮抗剂(G-15)、EGFR酪氨酸激酶抑制剂(AG1478)、HER2酪氨酸激酶抑制剂(AG825)、Src家族激酶抑制剂(PP2)或MMP抑制剂(GM6001)预处理2h后,再次检测HER2和ERK1/2的磷酸化水平变化.最后用Transwell方法检测G-1引起的MCF-7细胞迁移和侵袭能力的变化.结果 MCF-7细胞在用E2、4-OHT和G-1处理后,HER2和ERK1/2的磷酸化水平增加,该变化在用G-15、AG1478、AG825、PP2或GM6001预处理后受到抑制.而G-1引起的MCF-7细胞迁移和侵袭能力的增强也能被G-15、AG1478、AG825、PP2或GM6001抑制.结论 GPR30通过激活HER2-ERK1/2信号转导途径可促进MCF-7细胞的迁移和侵袭.